TheraPPI Bioscience is a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases, and inflammation.
Products, services, technology
TheraPPI’s first two programs target a protein interaction discovered by the founding team. Our first oncology program revolutionizes RAS-MAPK targeting: the new mode of action leverages 3 mechanisms with direct cancer-cell killing, no cancer resistance, and activation of a robust anti-tumor immune response.
- https://tppibio.com/
- Luc Otten
Some insights
TheraPPI Bioscience develops novel drugs that modify protein interactions to combat cancer drug resistance and to cure rare diseases.
We are proud to be at the forefront of developing drugs that target protein interactions for better patient outcomes.
The management team has a proven expertise in several key areas for a start-up: identification of novel therapeutic targets, discovery of PPI inhibitors, translational and early clinical development in oncology, and experience in finance.
We look for talent in drug discovery.
Enthusiasts and resilients.
Multiple interactions with most players of the Swiss biotech ecosystem.
